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The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a
positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L). Dys-
regulation of this pathway has been implicated in autoimmune diseases and cancer, and is
currently under clinical investigation as an immune checkpoint blockade. Here, we describe
the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution. A
central FDPPPF motif and residues within the CC’ loop of ICOS are responsible for the
specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in
comparison to other family members. Furthermore, our structure and binding data reveal that
the ICOS N110 N-linked glycan participates in ICOS-L binding. In addition, we report crystal
structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical eva-
luation in immunotherapy. Strikingly, antibody paratopes closely mimic receptor-ligand
binding core interactions, in addition to contacting peripheral residues to confer high binding
affinities. Our results uncover key molecular interactions of an immune complex central to
human adaptive immunity and have direct implications for the ongoing development of
therapeutic interventions targeting immune checkpoint receptors.
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Pathogenic infections trigger a series of highly regulatedevents orchestrated by the immune system to limit hostdamage and provide long-term protection. Upon encounter
of foreign antigens, antigen-presenting cells (APCs) display spe-
cific peptide major histocompatibility complexes (MHC) on their
surface that can be recognized by the T-cell receptors (TCR) of
naïve antigen-specific T cells. However, this first signal is not
sufficient for successful activation of T cells1, and a second
synergistic signal provided by interactions of co-stimulatory
receptors on T cells is required with their cognate ligands in
APCs2.
A key molecule that provides this secondary signal and hence
dictates T cell fate is the inducible T-cell co-stimulator (ICOS)3
and its unique ligand (ICOS-L) on APCs4,5. ICOS (CD278) is a
type I transmembrane glycoprotein that belongs to the CD28
family of co-stimulatory immunoreceptors. It is present on the T
cell surface as a disulfide bond-linked homodimer3 and it is
rapidly upregulated upon TCR cross-linking and/or CD28 co-
stimulation3,5,6. On the other hand, ICOS-L (CD275) belongs to
the B7 family and is expressed on the surface of APCs5,7,8 and
non-hematopoietic cells under inflammatory conditions9–12.
Binding of ICOS-L to ICOS triggers distinct intracellular signal-
ing cascades through the conserved motifs YMFM13, IProx14, and
KKKY15 in the ICOS cytoplasmic tail. These signaling pathways
deliver the co-stimulatory signals that promote T cell activation
and differentiation.
Multiple studies support a multifaceted function for ICOS/
ICOS-L and hence a complex role in dictating the course of
adaptive immunity. Individuals with null mutations in the ICOS
gene16 and ICOS-deficient animal models17–19 exhibit a profound
defect in humoral responses due to the lack of T follicular helper
(Tfh) cells, a specialized CD4+ T cell subset essential for germinal
center (GC) formation20. In addition to regulating thymus-
dependent (TD) Ab responses, ICOS also affects Th1, Th2, and
Th17 immunity21,22 and the homeostasis of regulatory T cells
(Treg)23. The expression of ICOS has also been reported in innate
lymphoid cells (ILCs), which expands the role of this receptor to
the innate arm of the immune system24. This multiplicity of roles
underpins the relevance of the ICOS/ICOS-L signaling pathway
and in turn, the tremendous potential of manipulating this co-
stimulatory signal in the development of cancer immunotherapies
and in the treatment of autoimmune diseases.
Various studies have demonstrated that anti-tumor T cell
responses in mice can be significantly boosted by combining
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade
with ICOS engagement25,26. In addition, emerging evidence
suggests that ICOS blockade holds promise for the treatment of
inflammatory diseases such as allergic asthma24. Anti-ICOS
monoclonal antibody (mAb) therapy that blocks ICOS signaling
has proven beneficial in the transplant field by inducing tolerance
following cardiac allograft in rats27–29. As a consequence, the
number of antibodies targeting the ICOS/ICOS-L immune
complex entering clinical trials is rapidly increasing. In particular,
the humanized monoclonal anti ICOS-L antibody prezalumab
has recently shown efficacy in the treatment of patients with
systemic lupus erythematosus (SLE) in a phase Ib clinical trial30.
Despite the importance of the ICOS/ICOS-L interaction in
modulating many aspects of adaptive immunity and the growing
evidence of the benefits of targeting this immune complex for
therapeutic interventions, the molecular details of how the
extracellular domains of this receptor/ligand pair interact and
how leading therapeutic antibodies recognize their targets remain
elusive.
Here, we report the crystal structure of the co-complex
between human ICOS and its ligand ICOS-L at 3.3 Å resolu-
tion, which reveals the molecular details of immune receptor
specificity. Furthermore, we describe the structural basis of
the interactions of two therapeutic antibodies with ICOS
and ICOS-L, respectively. Together, our structural characteriza-
tions uncover the molecular blueprints of the ICOS/ICOS-L
interaction and a detailed view of molecular mimicry achieved by
therapeutic antibodies to target the ICOS/ICOS-L signaling axis
in immunotherapy.
Results
Structure of the ICOS/ICOS-L complex. We determined the
molecular basis for the co-stimulatory signal provided by ICOS
(Fig. 1a) by solving the three-dimensional structure formed by the
extracellular domains of ICOS (residues 21–129) and its ligand
ICOS-L (residues 19–248) (Fig. 1b) at 3.3 Å resolution by x-ray
crystallography (Table 1). Truncation of ICOS at residue 129 and
therefore before C136, abolished the formation of disulfide-linked
homodimers and was required to obtain well-diffracting crystals.
The crystal structure reveals that ICOS adopts the predicted
single immunoglobulin (Ig) variable (V-type) domain archi-
tecture. ICOS-L is organized in two distinct domains: the most
apical domain (D1) adopts a V-type fold, whereas the membrane-
proximal domain (D2) adopts a C1-type fold (Fig. 1c).
ICOS/ICOS-L interact in a 1:1 receptor-ligand stoichiometry.
The main binding interface is formed by the FDPPPFK motif
(amino acids 114–120) located in the ICOS FG loop, which
interacts with residues from strands C and C’ and loops CC’ and
C’D of ICOS-L. These residues form a network of interactions
that include H-bonds and aromatic stacking (Fig. 1d, top). Single
alanine substitution of residues Q50, F114, and F119 drastically
impacted the binding of ICOS to ICOS-L to almost undetectable
levels (Fig. 1e), confirming the critical role of this interface for
receptor binding as previously reported31.
ICOS contains three putative N-linked glycosylation sites.
Clear electron density was observed in the co-complex crystal
structure for two N-acetyl glucosamine (GlcNAc) and three
mannose residues of the N-linked glycan at position N110.
Unexpectedly, ICOS-L residues F122, Q123, and E124 form H-
bonds with this ICOS glycan, which buries ~300 Å2 of surface
area on ICOS-L (Fig. 1d, bottom). Site-directed mutagenesis to
knock out this N-linked glycosylation site (N110Q) in ICOS led
to a faster on-rate and a slightly slower off-rate resulting in a 4.3-
fold improvement in binding affinity to ICOS-L (Fig. 1f). This
result suggests that the ICOS N110 glycan sterically gates ICOS-L
binding and that the buried surface area on ICOS-L represents
mere accommodation of the otherwise encumbering ICOS glycan
at the binding interface.
Comparison of ICOS and ICOS-L to other CD28 and B7 family
members. Superposition of the IgV domains of ICOS-L, B7-1,
and programmed cell death ligand-1 (PDL-1) revealed that the
angle of approach of ICOS to its ligand differs considerably from
that observed in related family members (Fig. 2a). In the CTLA-4/
B7 and PD1/PD-L1 complexes, the receptors cross the IgV
domains of their cognate ligands at ~110° and 90°, respectively.
However, in the ICOS/ICOS-L complex, the IgV domains cross at
150° (Fig. 2b).
These differences in disposition between the complexes are due
to their distinct receptor-ligand binding interfaces. Despite low
sequence identity (~20%), the overall structure of ICOS and
ICOS-L share many similarities with members of their respective
families (Fig. 3). Comparison of ICOS with CTLA-4 and CD28
reveal some degree of structural homology with a root mean
square deviation (r.m.s.d) of backbone atoms of 3.2 and 4.5 Å,
respectively, and a lower structural similarity with PD1 (r.m.s.d of
5.9 Å). Notably, the FDPPPF sequence in ICOS is analogous and
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remarkably structurally conserved to the invariant motif
MYPPPY present in the IgV domains of CD2832 and CTLA-
433,34 (backbone r.m.s.d of 0.45 and 0.39 Å, respectively). The
side chains of residues flanking the three central prolines are
similarly oriented in all structures as a result of the cis-trans-cis
arrangement of prolines. In contrast, the analogue motif
LAPKAQ in PD1 is not conserved either in sequence or in

























































































Fig. 1 Three-dimensional structure of the human ICOS/ICOS-L complex. a Schematic representation of the ICOS/ICOS-L co-stimulatory interaction.
Antigen-presenting cell (APC), T-cell receptor (TCR), Major Histocompatibility Complex (MHC), Inducible Co-stimulator (ICOS), Inducible Co-stimulator
ligand (ICOS-L). b Domain organization of ICOS and ICOS-L; signal peptide (SP), extracellular domains (D1-D2), transmembrane (TM) domain, and
cytoplasmic tail (CT). Disulfide bonding pattern is shown with red lines. Blue arrows indicate the length of the crystalized ectodomains. c Secondary
structure cartoon representation of the side view of the ICOS/ICOS-L complex. ICOS (deep teal, transparent surface) adopts a V-type Ig fold while ICOS-L
adopts a V-type Ig fold (wheat) followed by a C1-type Ig domain fold (orange). The helices are shown in light pink. d Detailed view of the receptor-ligand
interface. Top: the 114FDPPF119 motif in the FG loop of ICOS forms key hydrophobic interactions with aromatic residues from ICOS-L shown in stick
representation. Hydrogen bonds between ICOS and ICOS-L are shown as black dashed lines. Bottom: The blue mesh around the N110 glycan depicted as
sticks represent a composite omit electron density map contoured at 1.0 sigma. Colors are as in (c). e Kinetic binding curves of ICOS-L to ICOS WT and
ICOS mutants. Mutation of residues Q50, F114, and F119 abolished binding in BLI. f Comparison of the binding affinity (KD), association (on), and
dissociation (koff) rates of ICOS-L to WT ICOS and to ICOS N110 glycan knock-out mutant (N110Q). The mean values and standard deviation of three
biological replicates are shown.
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400 Å2 (64%), 360 Å2 (55%), 480 Å2 (71%), and 230 Å2 (28%) of
surface area to the binding interface of ICOS/ICOS-L, CTLA-4/
B7-1, CTLA-4/B7-2, and PD1/PDL-1, respectively.
A unique feature of ICOS, however, is its unusually long
strand C’ that protrudes from the surface of the ectodomain
leading to the formation of a ligand interaction not yet observed
in any of the previously solved CD28/B7 family complexes.
Specifically, binding of residues 66TKTKGS71 located in the
ICOS elongated strand C’ to ICOS-L buries 130 Å2 of surface
area, accounting for ~20% of the total BSA. Hence, although
the FDPPPF motif constitutes the core of the ICOS/ICOS-L
interface, residues TKTKGS in strand C’ together with residues
Q50, K52 in strand C contribute to the binding specificity of
ICOS (Fig. 3a).
Alignment of the B7 family proteins with ICOS-L show high
structural homology, with backbone r.m.s.d. ranging from 1.1 to
1.6 Å. Unsurprisingly, the primary structural difference observed
in ICOS-L with family members is found in the conformation of
loop C’D, which contacts strand C’ of ICOS (Fig. 3b). As a result,
the binding interface of ICOS-L is shifted toward the edge of the
AGFCC’ sheet and involves residues from strands F (L114, L116)
and C (Y51, Y53, Q55), as well as loops CC’ (K60, V62), C’D (I67,
Q69, N75) and FG (Q118, G121, F122). Consistently, mutations
in any of these residues were previously reported to result in a
substantial loss of receptor binding35.
Oligomeric engagement of the ICOS/ICOS-L immune com-
plex. Due to the ability of ICOS to form disulfide-linked homo-
dimers3 and the importance of surface oligomerization to trigger
its co-stimulatory signal, we measured binding affinity and
binding avidity of the ICOS/ICOS-L complex by biolayer inter-
ferometry (BLI) (Fig. 4). Binding of the ICOS-L ectodomain
monomer to the ICOS ectodomain immobilized as an array on the
biosensors showed a relatively low binding affinity (KD= 722 nM)
and very rapid off-rates (Koff= 1.6 × 10−1 s−1) (Fig. 4, top panel
and Supplementary Table 1). In contrast, by flipping the orien-
tation of the interaction and measuring binding avidity of ICOS
disulfide-linked homodimers to immobilized ICOS-L arrayed on
the biosensor, two orders of magnitude difference in the apparent
binding affinity constant (KD= 10 nM) was obtained (Fig. 4,
bottom panel and Supplementary Table 1). Such high avidity
might reflect clustering and oligomerization of ligands and
receptors at the cell surface upon T-cell activation and is in
agreement with the propensity of ICOS and ICOS-L to form
homodimers at the cell membrane3,35.
Our molecular data provide partial insight into the oligomeric
assembly of ICOS and ICOS-L. Indeed, in the absence of an
interchain disulfide bond, ICOS exists as a monomer in solution
(Supplementary Fig. 2a). In our crystal structure where the ICOS
interchain disulfide bond has been truncated, we observe an
ICOS/ICOS-L interface that buries ~420 Å2 of BSA (Supplemen-
tary Fig. 2b). This interaction could be indicative of an ICOS
dimeric interface present at the cell membrane; however, in this
crystallographic arrangement the ICOS protomers are oriented in
a head to tail fashion with the C-terminal tails (where the cysteine
residues would mediate putative disulfide bonds) pointing away
from each other (Supplementary Fig. 2c). As such, in the absence
of functional data supporting this dimeric interface, we propose
that the antiparallel ICOS dimer arrangement observed in the
crystal lattice is likely an artefact of crystal packing. Altogether,
Table 1 Data collection and refinement statistics.
ICOS/ICOSL/VNAR ICOSL/Prezalumab/VNAR ICOS/STIM003/anti-kappa VHH
Data collection
Wavelength (Å) 1.00000 1.03316 0.97934
Space group P4(1)2(1)2 P2(1) C2
Cell dimensions
a,b,c (Å) 104.0, 104.0, 123.1 68.5, 152, 86.7 171.8, 49.0, 91.8
α, β, ɣ (○) 90, 90, 90 90, 104.1, 90 90, 101.9, 90
Resolution (Å) 40–3.30 (3.40–3.30) 40–3.15 (3.25–3.15) 40–2.38 (2.48–2.38)
No. molecules in ASU 1 2 1
No. total reflections 128,986 (4688) 209,889 (9398) 201,759 (20,592)
No. unique reflections 10,227 (406) 29,746 (1378) 30,150 (3223)
Multiplicity 11.8 (12.2) 7.0 (7.0) 6.6 (6.0)
Rmerge (%) 26.9 (78.6) 16.8 (67.0) 10.9 (60.8)
Rpim (%) 7.9 (23.0) 6.8 (27.4) 4.5 (25.8)
<I/σ I> 10.0 (1.7) 9.4 (1.7) 13.3 (2.1)
CC1/2 99.3 (62.8) 99.4 (76.2) 99.7 (73.2)
Completeness (%) 95.7 (97.9) 99.9 (100) 99.2 (94.0)
Refinement
Non-hydrogen atoms 3513 11,774 5245
Macromolecule 3301 11,580 5072
Solvent – – 153
Rwork/Rfree 0.224/0.267 0.201/0.256 0.203/0.260
Rms desviations
Bond lenghts (Å) 0.01 0.004 0.004
Bond angles (○) 1.14 0.81 0.72
Ramachandran plot
Favored regions (%) 98.1 95.2 97.7
Allowed regions (%) 1.4 4.7 2.3
B-factors (Å2)
Wilson B-factor 86.6 76.7 45.7
Average B-factors 85.8 81.3 49.6
Average macromolecule 83.9 80.8 49.6
Average solvent – – 44.6
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our data suggest that ICOS dimerization at the cell surface
probably involves a limited dimeric interface of the ectodomain
and that the ICOS ectodomain is mainly linked through the
disulfide bond at the C-terminal tail near the transmembrane
region (Supplementary Fig. 2d).
Therapeutic antibodies can compete with the ICOS/ICOS-L
interaction. Monoclonal antibodies STIM003 and prezalumab
target ICOS and ICOS-L, respectively and are currently under
clinical evaluation. Using BLI, we confirmed that binding of these
antibodies to their respective ligands prevents the formation of
the ICOS/ICOS-L immune complex (Fig. 5a). To elucidate the
molecular basis of ligand blockade by the antibodies, we solved
the crystal structures of ICOS/STIM003 Fab and ICOS-L/pre-
zalumab Fab complexes at 2.38 and 3.15 Å resolution, respectively
(Table 1).
Superposition of the ICOS structure, when crystallized in
complex with its natural ligand and in complex with STIM003,
showed high structural similarity (backbone r.m.s.d of 0.90 Å).
The binding interface of ICOS in the antibody complex was
strikingly similar to the one when bound to its natural ligand
(Fig. 5b). In both cases, binding is concentrated in the FG loop of
ICOS. However, the total buried surface area of ICOS is slightly
higher for the STIM003 interaction in comparison to the
interaction with ICOS-L (800 to 620 Å2, respectively), due to
additional interactions of the antibody with the C’C” loop and
the C” strand. Despite the high similarity of the contacted ICOS
surface, ICOS-L and STIM003 approach the receptor with
different angles of approach (Fig. 5b). Consequently, the ICOS
N110 glycan minimally interferes with binding to STIM003
(Supplementary Fig. 3 and Supplementary Table 1).
The crystal structure of the ICOS-L/prezalumab Fab complex
was obtained using a shark Variable New Antigen Receptor
(VNAR) Single Domain36 as a crystallography chaperone
(Supplementary Fig. 4a). The crystal structure revealed that ICOS
and prezalumab bind ICOS-L with a similar angle of approach,
and that the ICOS IgV domain is in a highly similar conformation
in both complexes (backbone r.m.s.d of 1.0 Å). Both molecules
interact with an overlapping surface on ICOS-L; however,
prezalumab makes additional contacts with strand F and loop
C’D of ICOS-L upon binding, leading to a higher BSA compared
to the natural complex (900 Å2 vs. 580 Å2, respectively) (Fig. 5c).
As a result of the extended interface, prezalumab binding is
proximal to N70 (Fig. 6a), a predicted N-linked glycosylation site.
However, the crystal structure reveals almost no interaction with
N70 or the N-linked glycan (BSA of 10 and 60 Å2, respectively)
therefore suggesting that binding of prezalumab to ICOS-L is
largely independent of N-glycosylation. Notably, the angle
between the ICOS-L IgV and IgC domains in the ICOS/ICOS-L
and ICOS-L/prezalumab Fab crystal structures differs by ~14°,
indicating flexibility that can be attributed to a largely flexible
linker and minimal interactions between the two ICOS-L Ig
domains (Supplementary Fig. 4b).
Antibody mimicry of the ICOS/ICOS-L interaction. Remark-
ably, residues at the core of the ICOS/ICOS-L interaction are also
central to the antibody complexes (ICOS/STIM003 and ICOS-L/
prezalumab) (Fig. 6a). Prezalumab uses the heavy chain com-
plementary determining region (CDR) 3 (HCDR3) to mimic the
central ICOS FG loop that engages with ICOS-L. On the other
hand, HCDR3, LCDR1, and LCDR2 residues of STIM003
resemble the hydrophobic residues of the ICOS-L front sheet that
drive the interaction with ICOS. A key feature of the antibody-
antigen interactions is that in addition to central hydrophobic
contacts that resemble the natural ligands, additional hydrogen
bonds and salt bridges form in the periphery (Fig. 6b). Indeed,
only five hydrogen bonds are formed at the binding interface
between ICOS and ICOS-L. In contrast, ten hydrogen bonds and
b
a
Fig. 2 Angle of ligand-receptor interactions for CTLA-4/B7 family
members. a Top view cartoon representation of ICOS/ICOS-L and
previously solved CTLA-4/B7-133 and PD1/PDL-169 complexes. The
orientation of the complexes are based on the structural alignment of the
ligands (different shades of brown). Receptors are shown as shades of
green. Structural features are labeled to help with orientation. b Angle of
approach of the three receptors to its ligands calculated using Pymol70.
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one salt bridge (ICOS/STIM003), and seven hydrogen bonds
(ICOS-L/prezalumab) are part of the antibody-antigen binding
interfaces. These additional interactions are concentrated in the
enlarged areas of the antibody interfaces that is solvent accessible
in the ICOS/ICOS-L complex (Fig. 5) and are presumably
responsible for the higher binding affinity of the antibodies
compared to the natural ligands (Fig. 6c and Supplementary
Table 1). Noteworthy, the mimicry of these two antibodies
compared to their cognate receptors is higher than any other
therapeutic antibodies targeting receptors/ligands in the same
family for which the three-dimensional structure has been
reported (Fig. 6d and Supplementary Fig. 5).
Discussion
T cell activation is mediated by the coordinated interplay of a
complex network of transmembrane co-stimulatory and co-
inhibitory receptor/ligand pairs. When dysregulated, T cell
responses can result in tissue damage leading to autoimmunity
or cancer. Thus, modulation of these molecular complexes to
repress or enhance immune responses is a powerful strategy in
immunotherapy. Important examples are provided by the
remarkable improvements in disease outcome obtained with
antibodies targeting CTLA-4 and PD137–40. ICOS, a member of
this family, has emerged as a promising target for immunother-
apy24–30 because of its central role in the T/B-cell co-signaling
pathway3 associated with adaptive and innate immunity21,41.
Our crystal structure of the ICOS/ICOS-L complex revealed
that ICOS adopts a predicted35 overall Ig-fold structure similar to
CTLA-4 and CD2842. These three surface receptors utilize a
central PPP motif disposed in a high-energy cis-trans-cis con-
formation that is flanked by aromatic residues to engage their
cognate ligands32–34. However, we show that unlike CTLA-4/
CD28, ICOS utilizes a second set of residues within its CC’ loop
to contribute a considerable fraction of the contacts likely
responsible for its binding specificity to ICOS-L. Interestingly,
identification of this second binding interface offers an oppor-
tunity to guide loop grafting strategies for the design of soluble
ligands with cross-reactivity between receptors. In line with this
idea, simultaneous blockade of the co-stimulatory receptors ICOS










Fig. 3 Specificity of the ICOS and ICOS-L interaction. Sequence alignment of (a), ICOS with CTLA-4 and PD1 and b, ICOS-L with B7-1, B7-2, and PDL-1.
Invariant residues (asterisk), and residues with highly (colon) and weakly similar properties (dot) are indicated. Strands and α helixes are denoted by
arrows and cylinders, respectively. Secondary structure cartoon representation of (a), the V-type domains of ICOS in comparison with CTLA-4 (PDB IDs:
1I8L and 1I85) and PD1 (PDB ID: 4ZQK) and (b), ICOS-L in comparison with B7-1 (PDB ID: 1I8L), B7-2 (PDB ID: 1I85) and PDL-1 (PDB ID: 4ZQK). Backbone
r.m.s.d. between ICOS and ICOS-L and structures of other family members is shown in parentheses and were calculated in Pymol70. Residues are shown as
surface and colored according to their BSA. Areas with higher and lower BSA in ICOS and ICOS-L with respect to the other family members are boxed in
red and blue, respectively. The total BSA of each ectodomain is indicated.
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survival in rats28. Therefore, we speculate that such cross-reactive
and biparatopic molecules could show beneficial therapeutic
properties for several disease indications, including allograft
transplantation, autoimmune diseases, and cancer.
Monovalent binding of ICOS to ICOS-L showed low affinity
and fast binding kinetics, while bivalent binding resulted in a two-
orders of magnitude stronger binding kinetics. Rapid off-
rates might be important to allow Tfh-cell motility into the B cell
zone in the GC through a dynamic formation and disruption of T
cell-APC contacts facilitating fast antigen scanning. This process
is governed by ICOS/ICOS-L interaction in a TCR-independent
manner43. However, efficient co-stimulatory signaling relies on
avidity for the formation of oligomeric structures with high sta-
bility at the immunological synapse. Interestingly, this depen-
dence on binding avidity observed for ICOS has been previously
reported for CTLA-4 homodimers, but not for CD28 homo-
dimers44. Indeed, CTLA-4 and B7-1 can form a zipper-like oli-
gomerization of disulfide-linked CTLA-4 homodimers and B7-1
homodimers33. On the contrary, CD28 homodimers are incom-
patible with the simultaneous binding of two B7-1 molecules due
to clashes of the membrane-proximal domain of the ligand42. Our
crystal structure of the ICOS/ICOS-L monomeric complex did
not allow to define a biologically relevant dimer interface for the
ICOS ectodomain; indeed, a mutation removing the interchain
disulfide bond in ICOS was required to obtain well-diffracting
crystals, resulting in the ICOS ectodomain being monomeric in
solution and limited information could be derived from the
crystal packing interfaces. Similarly, monomeric forms of CTLA-
4 in solution have been reported in the absence of the disulfide
linkage32,45. This observation, together with the capacity of ICOS
and CTLA-4 to simultaneously bind two ligand molecules, sug-
gest that ICOS and ICOS-L may leverage a periodic arrangement
of receptor-ligand complexes at the T-cell-APC interface similar
to the one reported for the CTLA-4/B7-1 complex. However,
future studies will be required to precisely define the oligomeric
assembly of these molecules at the immune synapse.
A notable feature uncovered by our ICOS/ICOS-L co-complex
structure is the presence of ICOS N-linked glycan N110 at the
binding interface. The N110Q mutation removing this N-linked
glycan resulted in a 4.3-fold improvement in binding affinity of
ICOS to ICOS-L. Such a role of N-linked glycosylation mod-
ulating receptor binding was also reported in previous studies
where deglycosylation of CD28 was found to enhance binding to
CD80 on APC46, and a hypoglycosylated form of B7-2 showed
reduced binding to CD28 and CTLA-447. Importantly, abnormal
glycosylation of cell surface proteins can influence signaling
pathways implicated in cell survival and growth-promoting sev-
eral disorders, including cancer48. For example, a recent study
reported that N-glycan modification of PD-L1 on triple-negative
breast cancer cells was essential for PD-1 interaction and there-
fore T cell exhaustion49. It remains to be determined how ICOS
glycosylation is impacted in dysregulated cells, and how such
modifications in the presence and composition of the N110 gly-
can may impact disease progression. Nonetheless, our findings
contribute further evidence of post-translation modifications, and
particularly glycobiology in modulating binding thresholds, in
this case relevant for T cell activation.
Therapeutic antibodies with an antagonistic mode of action
often compete with natural ligands50, and their efficacy is linked
to the extent of epitope overlap with the natural ligand footprint.
Yet, steric overlap is rarely achieved by exact mimicry of the
native molecular interactions. Strikingly, our crystallographic
studies revealed that two therapeutic antibodies, STIM003 and
prezalumab, contact almost all residues involved in the ICOS/
ICOS-L immune complex interaction. Comparison to other
therapeutic antibody-ligand structures in the checkpoint blockade
family (PD1, PDL-1, and CTLA-4) revealed that the level of
mimicry observed for STIM003 and prezalumab is remarkable.
Accordingly, our structural data suggest that the reported
antagonistic effect of prezalumab51 is likely attributed to efficient
outcompeting ICOS for binding to ICOS-L, in addition to pos-
sible steric hindrance that block receptor-ligand clustering at the
membrane surface. The level of mimicry achieved by the ICOS
and ICOS-L therapeutic antibodies described here approaches
some of the previous reports in the field of infectious diseases
where antibodies against viral envelope proteins precisely target
specific conserved receptor-interacting residues to avoid viral
escape52–55. The molecular principles derived from our structures
will continue to inform de novo structure-based strategies for the
design of biologics that showcase natural mimicry, as also
recently exemplified by the design of selective mimics of IL-2 and
IL-1556.
A detailed analysis of the binding interface of ICOS/STIM003
and ICOS-L/prezalumab also revealed a slightly larger footprint
compared to the binding interface of the receptor-ligand pair, and
the presence of additional hydrogen bonds and salt bridges in the
periphery of the core interaction. In the BioMuta sequence
database of cancer patients57, eight single nucleotide variations
(SNVs) compiled in the ICOS sequence (S76P, G70R, N73Y,
K78N, F114V, P116S, P116H, and P117A) and two in the ICOS-L
sequence (Y51C and Y65H) were identified as antibody-contact
residues (Supplementary Fig. 6a). How these SNVs will impact
therapeutic responses is an area of future investigation now
possible from the precise delineation of these antibody epitopes.
Together, our data provide critical knowledge to better
understand the molecular basis of the APC/T cell interaction, and
the atomic blueprints for the design of next-generation biologics
to modulate the ICOS/ICOS-L therapeutic axis.
Methods
ICOS and ICOS-L expression and purification. The ectodomains of human ICOS
(UniprotKB Q9Y6W8) (residues 21–138) and ICOS-L (UniprotKB O75144)
(residue 19–248) followed by a tobacco etch virus (TEV) cleavage site were fused to
a monomeric variant of Venus58 to promote expression of the glycoproteins. Genes
were synthesized at GeneArt (Life Technologies) and cloned into the pHLsec
expression vector containing a C-terminal His6x tag for downstream purification.
Proteins were expressed in HEK 293F cells (ThermoFisher Scientific) following
standard protocols59: about 200 mL of cells were seeded at a density of 0.8 × 106
cells/mL and incubated with 125 rpm oscillation at 37 °C, 8% CO2, and 70%

































Fig. 4 Binding of recombinant ICOS and ICOS-L ectodomains. Schematic
experimental set-up (left) and kinetic binding curves (right) for immobilized
ICOS and ICOS-L as analyte (top) and inverted system (bottom) measured
by BLI.
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humidity in a Multitron Pro shaker (Infors HT). Twenty-four hours after seeding,
cells were transiently transfected using 50 μg of filtered DNA preincubated for
10 min at room temperature (RT) with the transfection reagent FectoPRO (Poly-
plus Transfections) in a 1:1 ratio. Cell suspensions were harvested by centrifugation
at 5000 × g for 15 min after 6–7 days and the supernatants were passed through a
HisTrap Ni-NTA column (GE Healthcare) at 4 ml min−1. After washing the
column with 20 mM Tris pH 9.0, 150 mM NaCl, 5 mM imidazole, ICOS-Venus,
and ICOS-L-Venus were eluted with an increasing gradient of imidazole (up
to 500 mM). Fractions containing protein were pooled and digested for 1 h at RT
with the TEV protease. Digested protein was recovered in the flow through of a
second HisTrap Ni-NTA column, concentrated and loaded onto a Superdex
200 Increase size exclusion column (GE Heathcare) in 20 mM Tris pH 9.0, 150 mM
NaCl buffer.
Expression and purification of ICOS and ICOS-L complexes. For structure
determination of the ICOS/ICOS-L complex, a shark Variable New Antigen
Receptor (VNAR) Single Domain targeting the constant domain of ICOS-L was
used36. The ternary complex was produced by co-transfecting the DNA encoding
ICOS (residues 21–129): ICOS-L (residues 19–248):VNAR in a 3:1:4 ratio.
Similarly, the ICOS-L/prezalumab complex was produced in the presence of VNAR
by co-transfecting ICOS-L:FabHC: FabLC:VNAR in a 2:2:1:4 ratio. The ICOS/
STIM003 complex was obtained by co-transfection of ICOS C136AC137A N23Q
(residues 21–138):FabHC:FabLC in a 2:2:1 ratio. Cys mutations were required to
increase sample homogeneity and obtain well-diffracting crystals. The DNA ratios
used in each transfection was selected based on the expression yields of the indi-
vidual proteins with the aim to achieve similar expression levels between them
when co-transfecting. In order to obtain samples of homogeneous glycan com-
position that would allow downstream processing and efficient crystal packing, the
three complexes were expressed in HEK 293S cells (Gnt I−/−). After harvesting the
cells, the supernatant was loaded onto a HisTrap Ni-NTA column and the complex
eluted with a gradient of imidazole. Upon buffer exchange to remove the imidazole,
Venus and glycans were cleaved by incubating with TEV and EndoH, respectively
for 1 h at 37 °C. The digested complex was collected from the flow through of a
second HisTrap Ni-NTA column, concentrated and loaded onto a Superdex 200
Increase size exclusion column (GE Heathcare) in 20 mM Tris pH 9.0, 150 mM
NaCl buffer. In addition, for the ICOS/ICOS-L complex, the fractions containing
protein were buffer exchanged to 20 mM Tris pH 9.0, loaded on a MonoQ ion
exchange column and eluted with a 0–50% linear gradient of 1 M potassium
















































Fig. 5 Recognition of ICOS and ICOS-L by therapeutic antibodies. a Antibody binding competition of ICOS-L (immobilized) to ICOS or ICOS+ STIM003
Fab (left); and ICOS (immobilized) to ICOS-L or ICOS-L+ Prezalumab Fab (right). Comparison between the structures of the ICOS/ICOS-L complex and
b the ICOS/STIM003 complex and c the ICOS-L/prezalumab complex. The light and the heavy chains of STIM003 are colored in light and dark pink,
respectively while the prezalumab light and the heavy chains are colored in gray and blue, respectively. ICOS (deep teal) and ICOS-L (wheat) are rotated
90° about a horizontal axis to reveal the binding surface of the antibodies. Epitope traces of STIM003 (pink) and ICOS-L (wheat) are depicted on the
surface of ICOS, and prezalumab (blue) and ICOS (deep teal) on the surface of ICOS-L.
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Fab expression and purification. The Fab heavy and light chains of STIM003 and
prezalumab were cloned into custom pcDNA3.4 expression vectors at GeneArt
(Life Technologies). Fabs were transiently expressed in 200 mL HEK 293F cells
(ThermoFisher Scientific) by co-transfecting 90 μg of the LC and the HC in a 1:2
ratio with FectoPRO (Polyplus Transfections). Purification of the Fabs was per-
formed using a KappaSelect affinity column (GE Healthcare) and 100 mM glycine
pH 2.2 as the elution buffer. Eluted fractions were immediately neutralized with 1
M Tris-HCl pH 9.0 and further purified using a MonoS ion exchange column and a
Superdex 200 Increase size exclusion column (GE Healthcare).
Crystallization and X-ray data collection. Purified complexes were concentrated,
mixed 1:1 with mother liquor and set up in sitting drop vapor diffusion crystal-
lization experiments. The ICOS/ICOS-L/VNAR complex was concentrated to 10
mg/mL and crystals grew in 0.1 M HEPES, pH 7.0, and 30% (v/v) Jeffamine ED-
2001 and were cryoprotected with 15% (v/v) glycerol. X-ray diffraction data were
collected at the 17-ID-B synchrotron beamline at the Advanced Photon Source
(APS) at the Argonne National Laboratory. The ICOS-L/prezalumab/VNAR
complex was concentrated to 12 mg/mL and grown in 0.2 M di-ammonium tartrate
and 20% (w/v) PEG 3350 and cryoprotected with 10% (v/v) glycerol. X-ray dif-
fraction data were collected at the 23-ID-B synchrotron beamline at APS. To
determine the structure of the ICOS/STIM003 complex, the purified complex was
incubated with a variable heavy-chain (VHH) domain specific for the human kappa
light chain as a crystallization chaperone60 in a 1:5 ratio for 30 min at RT followed
by gel filtration chromatography (Superdex 200 Increase size exclusion column, GE
Healthcare) in 20 mM Tris pH 9.0, 150 mM NaCl buffer. The purified sample was
concentrated to 4 mg/mL and crystals were obtained in 0.2 M di-sodium hydrogen
phosphate and 20% (w/v) polyethylene glycol 3350 and cryoprotected with 10% (v/
v) glycerol. X-ray diffraction data were collected at the FMX synchrotron beamline
at the National Synchrotron Light Source II (NSLS-II) at Brookhaven National
Laboratory (BNL). Data from the three complexes were processed using XDS61 and
the structures were solved by molecular replacement using Phaser62. CTLA-433,
B7-H363, B7-1 D233, Fabs from our internal database, and VNAR type 164 were
used as search models for ICOS, ICOS-L D1, ICOS-L D2, the Fabs, and VNAR,
respectively. The refinement of the structures was carried out by iterative rounds of
phenix.refine65 and manual building in Coot66. Representative electron density for
the three structures is shown in Supplementary Fig. 6b–d. EMBL-EBI-PDBePISA67
was used to calculate the reported buried surface area. Access to all software was
supported through SBGrid68.
Biolayer interferometry. Binding affinity measurements were conducted by BLI
using an Octet RED96 BLI system (Pall ForteBio) in PBS pH 7.4, 0.01% BSA, and
0.002% (v/v) Tween. Ni-NTA biosensors were used to bind His-tagged ICOS and
ICOS-L proteins. A signal response of 0.8 nm was reached before transferring the
loaded biosensors to wells containing a 1:2 serial dilutions of the Fabs or of the





























































Fig. 6 Remarkable receptor mimicry by antibodies targeting ICOS/ICOS-L. a Antibody mimicry of the main hydrophobic/aromatic interface of the ICOS/
ICOS-L complex by STIM003 and prezalumab. HCDR3 of prezalumab mimics the FG loop of ICOS to mediate interaction with ICOS-L (left panel).
STIM003 interactions with the FG loop of ICOS are mediated by residues from HCDR3, LCDR1 and LCDR2 (right panels). Critical residues for binding are
shown in sticks and the BSA of these and the rest of residues involved in binding are plotted (bottom). The BSA of the ICOS/ICOS-L interaction is included
for direct comparison. b Additional H-bonds (black dashes) between the antibodies and ICOS and ICOS-L in areas outside the core interface of the
receptor/ligand complex. c Kinetics of prezalumab and STIM003 binding to ICOS-L and ICOS, respectively. d Comparison of binding mimicry by
therapeutic antibodies targeting the CD28/B7 superfamily calculated as the fraction of residues with >1 Å2 of BSA of the receptor/ligand pair that are
contacted by antibody binding as detailed in Supplementary Fig. 5. Color coding is as in Fig. 4.
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untagged ICOS-L and ICOS, respectively. Initial concentrations of 125, 500, and 31
nM were used for ICOS (wild-type and mutants), ICOS-L and prezalumab,
respectively when used as analytes. The duration of each association and dis-
sociation steps was 180 s. The analysis was performed using the Octet software,
with a 1:1 fit model. A minimum of three replicates for each binding curve was
done. Supplementary Table 1 contains the averaged values and the calculated
standard deviations of the kinetic measurements.
Data availability
The crystal structures reported in this manuscript are available from the Protein Data
Bank under accession codes 6X4G (ICOS/ICOS-L/VNAR complex), 6X4T (ICOS-L/
Prezalumab/VNAR complex), and 7JOO (ICOS/STIM003/anti-kappa VHH complex).
Other data are available from the corresponding author upon reasonable request.
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